FY2024 EPS Estimates for Entera Bio Reduced by HC Wainwright

Entera Bio Ltd. (NASDAQ:ENTX) – HC Wainwright reduced their FY2024 earnings per share estimates for Entera Bio in a research note issued on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.28) per share for the year, down from their prior forecast of ($0.23). HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Entera Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Entera Bio’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.16) EPS and FY2025 earnings at ($0.55) EPS.

Entera Bio Price Performance

Shares of Entera Bio stock opened at $1.73 on Thursday. Entera Bio has a 1 year low of $0.52 and a 1 year high of $3.35. The stock has a market cap of $61.90 million, a PE ratio of -6.65 and a beta of 1.58. The firm has a fifty day moving average price of $1.85 and a 200 day moving average price of $1.91.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ENTX. Virtu Financial LLC acquired a new stake in Entera Bio during the first quarter valued at $37,000. Signature Estate & Investment Advisors LLC acquired a new position in Entera Bio during the third quarter worth $90,000. Finally, Parkman Healthcare Partners LLC raised its position in Entera Bio by 2.4% during the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock worth $781,000 after acquiring an additional 9,558 shares during the period. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.